Showing 1891-1900 of 7383 results for "".
VShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF TechnologySupport for Population- Based Skin Cancer Screenings
https://practicaldermatology.com/topics/skin-cancer-photoprotection/support-for-population--based-skin-cancer-screenings/21675/A new study offers data to show that general skin cancer screenings by dermatologists and properly trained physicians can reduce morbidity and mortality.Sunscreen Labeling
https://practicaldermatology.com/topics/practice-management/sunscreen-labeling-/19370/Neal Bhatia, MD discusses the impact of new sunscreen labeling on patient education, as well as strategies for UV avoidance, and trends in therapeutic development.Body Contouring
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/body-contouring/19413/Dr. Amy Derick discusses the latest way to achieve a leaner, more sculpted look with CoolSculpting® by Zeltiq®.Can UV Nail Dryers Cause Skin Cancer?
https://practicaldermatology.com/topics/hair-nails/can-uv-nail-dryers-cause-skin-cancer/23898/Alexis Livingston Young, MD, weighs in on the evidence.The Biologic Coordinator: Your Partner to Access
https://practicaldermatology.com/columns/biologic-coordinator/the-biologic-coordinator-your-partner-to-access/24032/As the biologics market has increased, so might your practice’s need for a biologic coordinator.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Dispatches from the 2022 Skin of Color Update
https://practicaldermatology.com/conferences/skin-of-color-update-2022/dispatches-from-the-2022-skin-of-color-update/23822/Co-chair Dr. Andrew F. Alexis shares highlights from the recent meeting.Success Factors in Selling A Dermatology Practice
https://practicaldermatology.com/topics/practice-management/success-factors-in-selling-a-dermatology-practice/23499/What to do if you’re considering a sale or merger.Reclaiming “Quality” in Dermatology
https://practicaldermatology.com/topics/practice-management/reclaiming-quality-in-dermatology/23432/Dermatologists know quality care when they see it. It’s time to take an active role in defining meaningful quality measures.